相关实验视频
Updated: Aug 1, 2026
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
维生素C改善了慢性心力衰竭患者的导管动脉内皮功能
Circulation
|February 19, 1998
概括
维生素C通过增加氧化的可用性来改善慢性心力衰竭中的流量依赖扩张. 这表明抗氧化剂可以对抗心力衰竭患者内皮功能障碍.
科学领域:
- 心血管医学 心血管医学
- 内皮功能研究研究 内皮功能研究
- 抗氧化剂治疗研究 抗氧化剂治疗研究
背景情况:
- 慢性心力衰竭 (CHF) 与内皮功能障碍有关,特别是流量依赖扩张 (FDD) 的受损.
- 在CHF中激素形成的增加可能会使氧化失活,从而导致内皮功能障碍.
- 这项研究调查了抗氧化剂维生素C在治疗CHF患者的FDD中的作用.
研究的目的:
- 确定维生素C对慢性心力衰竭 (CHF) 患者的流量依赖扩张 (FDD) 的影响.
- 测试假设,CHF中内皮功能受损是由于氧化物被基因激素无活化的原因.
主要方法:
- 利用高分辨率超声波和多普勒测量15名心血管衰竭患者和8名健康志愿者的辐射动脉直径和血流.
- 服用维生素C (25毫克/分钟IA) 和安慰剂,评估静止状态和反应性高血压期间的血管影响.
- 在维生素C注射前后,用N-单甲基-L-氨酸 (L-NMMA) 抑制氧化合成.
主要成果:
- 维生素C在急性动脉内给药 (13.2%与8.2%) 和4周口服治疗 (11.9%与8.2%) 后,在CHF患者中显著恢复FDD.
- 在急性和慢性维生素C治疗后,FDD的氧化介导部分显著增加.
- 结果表明,维生素C通过增加CHF患者的氧化可用性来增强FDD.
结论:
- 维生素C的使用改善了慢性心力衰竭患者的流量依赖扩张.
- 提高氧化的可用性是维生素C改善CHF中FDD的机制.
- 这些发现支持这样一个假设:激素诱导的氧化降解有助于CHF的内皮功能障碍.
相关概念视频
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...